(Hypertension. 1995;26:602-609.)
© 1995 American Heart Association, Inc.
Renal Circulation and Blockade of the Renin-Angiotensin System
Is Angiotensin-Converting Enzyme Inhibition the Last Word?
From Brigham and Women's Hospital and Harvard Medical School, Departments of Radiology and Medicine, Boston, Mass.
Abstract The mechanism by which angiotensin-converting enzyme (ACE) inhibition influences renal perfusion and function has assumed growing importance as alternatives for blocking the system have emerged. Neither renin inhibitors nor angiotensin II (Ang II) antagonists are likely to trigger responses similar to ACE inhibitor–induced involvement of kinins, prostaglandins, or nitric oxide. Several observations suggest species variation in the contribution of these pathways to the renal response to ACE inhibition. In humans, recent investigation suggests that virtually all of the renal response is due to a fall in Ang II formation. Perhaps most persuasive is the surprising observation that the renal hemodynamic response to renin inhibitors exceeds by more than 50% the response to ACE inhibition in healthy humans. To the extent that kinins or prostaglandins contribute to the renal response to ACE inhibition, one would anticipate a smaller response to renin inhibition. Possible explanations include an unanticipated additional action of renin inhibitors, better tissue penetration of these highly lipophilic agents, or more effective blockade of Ang II formation through an action at the rate-limiting step or non–ACE-dependent Ang II generation. Substantial evidence favors the latter two possibilities. Whatever the explanation, these observations raise the intriguing possibility that the undoubted therapeutic efficacy of ACE inhibition in renal injury, documented most rigorously for type I diabetes mellitus, might be exceeded with the newer classes of agent.
Key Words: prostaglandins • renin • angiotensin II • kinins
This article has been cited by other articles:
 |
|
 |
|
  N. D.L. Fisher, A.H. Jan Danser, J. Nussberger, W. P. Dole, and N. K. Hollenberg Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans Circulation, June 24, 2008; 117(25): 3199 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Segall, A. Covic, and D. J. A. Goldsmith Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2435 - 2439. [Full Text] [PDF]
|
|
|
|
 |
|
 N. D.L. Fisher and N. K. Hollenberg Renin Inhibition: What Are the Therapeutic Opportunities? J. Am. Soc. Nephrol., March 1, 2005; 16(3): 592 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stanton, C. Jensen, J. Nussberger, and E. O'Brien Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren Hypertension, December 1, 2003; 42(6): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Stanton Review: Potential of renin inhibition in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2003; 4(1): 6 - 10. [Abstract] [PDF]
|
|
|
|
|
|
N. K Hollenberg Review: The renin-angiotensin-aldosterone system, blockade and diabetic nephropathy Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S185 - S187. [PDF]
|
|
|
|
 |
|
 M. Bertrand, G. Godet, K. Meersschaert, L. Brun, E. Salcedo, and P. Coriat Should the Angiotensin II Antagonists be Discontinued Before Surgery? Anesth. Analg., January 1, 2001; 92(1): 26 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ruilope RAS blockade: new possibilities in the treatment of complications of diabetes Heart, September 1, 2000; 84(90001): 32i - 34. [Full Text]
|
|
|
|
|
|
P. van Paassen, D. de Zeeuw, G. Navis, and P. E. de Jong Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function Nephrol. Dial. Transplant., May 1, 2000; 15(5): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Rodby, R. D. Rohde, W. R. Clarke, L. G. Hunsicker, D. A. Anzalone, R. C. Atkins, E. Ritz, and E. J. Lewis The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics Nephrol. Dial. Transplant., April 1, 2000; 15(4): 487 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. PRICE, L. E. PORTER, M. GORDON, N. D. L. FISHER, J. M. F. DE'OLIVEIRA, L. M. B. LAFFEL, D. R. PASSAN, G. H. WILLIAMS, and N. K. HOLLENBERG The Paradox of the Low-Renin State in Diabetic Nephropathy J. Am. Soc. Nephrol., November 1, 1999; 10(11): 2382 - 2391. [Abstract] [Full Text]
|
|
|
|
|
|
S. Y. Osei, D. A. Price, N. D. L. Fisher, L. Porter, L. M. B. Laffel, and N. K. Hollenberg Hyperglycemia and Angiotensin-Mediated Control of the Renal Circulation in Healthy Humans Hypertension, January 1, 1999; 33(1): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Springate, L. G. Feld, and D. Ganten Enalapril and Renal Function in Hypertensive Rats Transgenic for Mouse Renin Gene Hypertension, October 1, 1997; 30(4): 868 - 872. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Price, J. M. De'Oliveira, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy Men Hypertension, August 1, 1997; 30(2): 240 - 246. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Wolny, J.-P. Clozel, J. Rein, P. Mory, P. Vogt, M. Turino, W. Kiowski, and W. Fischli Functional and Biochemical Analysis of Angiotensin II–Forming Pathways in the Human Heart Circ. Res., February 1, 1997; 80(2): 219 - 227. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. J. Materson ACE Inhibitors as a Shield Against Diabetic Nephropathy Arch Intern Med, February 12, 1996; 156(3): 239 - 240. [Abstract] [PDF]
|
|